Organization
SMT Bio
1 clinical trial
1 abstract
Clinical trial
Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2025-01-08
Abstract
Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.Org: Yonsei University College of Medicine, Severance Hospital, SMT Bio, SMT bio Co.Ltd,